...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Chronic Obstructive Pulmonary Disease >Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – a network meta-analysis
【24h】

Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – a network meta-analysis

机译：150μg和300μg茚达特罗与福莫特罗+布地奈德或沙美特罗+氟替卡松固定剂量组合治疗慢性阻塞性肺疾病的比较疗效-网络荟萃分析

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To compare efficacy of indacaterol to that of fixed-dose combination (FDC) formoterol and budesonide (FOR/BUD) and FDC salmeterol and fluticasone (SAL/FP) for the treatment of chronic obstructive pulmonary disease (COPD) based on the available randomized clinical trials (RCTs).Methods: Fifteen placebo-controlled RCTs were included that evaluated: indacaterol 150 μg (n = 5 studies), indacaterol 300 μg (n = 4), FOR/BUD 9/160 μg (n = 2), FOR/BUD 9/320 μg (n = 3), SAL/FP 50/500 μg (n = 5), and SAL/FP 50/250 μg (n = 1). Outcomes of interest were trough forced expiratory volume in 1 second (FEV1), total scores for St. George's Respiratory Questionnaire (SGRQ), and transition dyspnea index (TDI). All trials were analyzed simultaneously using a Bayesian network meta-analysis and relative treatment effects between all regimens were obtained. Treatment-by-covariate interactions were included where possible to improve the similarity of the trials.Results: Indacaterol 150 μg resulted in a higher change from baseline (CFB) in FEV1 at 12 weeks compared to FOR/BUD 9/160 μg (difference in CFB 0.11 L [95% credible intervals: 0.08, 0.13]) and FOR/BUD 9/320 μg (0.09 L [0.06, 0.11]) and was comparable to SAL/FP 50/250 μg (0.02 L [–0.04, 0.08]) and SAL/FP 50/500 μg (0.03 L [0.00, 0.06]). Similar results were observed for indacaterol 300 μg at 12 weeks and indacaterol 150/300 μg at 6 months. Indacaterol 150 μg demonstrated comparable improvement in SGRQ total score at 6 months versus FOR/BUD (both doses), and SAL/FP 50/500 μg (–2.16 point improvement [–4.96, 0.95]). Indacaterol 150 and 300 μg demonstrated comparable TDI scores versus SAL/FP 50/250 μg (0.21 points (–0.57, 0.99); 0.39 [–0.39, 1.17], respectively) and SAL/FP 50/500 μg at 6 months.Conclusion: Indacaterol monotherapy is expected to be at least as good as FOR/BUD (9/320 and 9/160 μg) and comparable to SAL/FP (50/250 and 50/500 μg) in terms of lung function. Indacaterol is also expected to be comparable to FOR/BUD (9/320 and 9/160 μg) and SAL/FP 50/500 μg in terms of health status and to SAL/FP (50/250 and 50/500 μg) in terms of breathlessness.
机译：目的：比较茚达特罗与固定剂量联合用药（FDC）福莫特罗和布地奈德（FOR / BUD）以及FDC沙美特罗和氟替卡松（SAL / FP）在治疗慢性阻塞性肺疾病（COPD）方面的疗效。方法：包括15项安慰剂对照RCT，评估的药物为：茚达特罗150μg（n = 5研究），茚达特罗300μg（n = 4），FOR / BUD 9/160μg（n = 2）。 ，FOR / BUD 9/320μg（n = 3），SAL / FP 50/500μg（n = 5）和SAL / FP 50/250μg（n = 1）。感兴趣的结果包括：1秒钟的强迫呼气量（FEV1），圣乔治呼吸问卷的总分（SGRQ）和过渡呼吸困难指数（TDI）。使用贝叶斯网络荟萃分析同时分析所有试验，并获得所有方案之间的相对治疗效果。结果：茚达特罗150μg与FE / BUD 9/160μg相比，FEV1在12周时相对于基线（CFB）的变化更大，差异有统计学意义。 CFB 0.11 L [95％可信区间：0.08，0.13]）和FOR / BUD 9/320μg（0.09 L [0.06，0.11]），与SAL / FP 50/250μg（0.02 L [–0.04，0.08] ]）和SAL / FP 50/500μg（0.03 L [0.00，0.06]）。 12周时茚达特罗300μg和6个月时茚达特罗150/300μg观察到相似的结果。 150克茚达特罗在6个月时的SGRQ总得分与FOR / BUD（两种剂量）和SAL / FP 50/500毫克相比均有可比的改善（–2.16点改善[–4.96，0.95]）。在6个月时，茚达特罗150和300μg的TDI评分与SAL / FP 50/250μg（分别为0.21点（–0.57，0.99）; 0.39 [–0.39，1.17]）和SAL / FP 50/500μg相当。 ：茚达特罗单药治疗的肺功能预期至少与FOR / BUD（9/320和9/160μg）一样好，与SAL / FP（50/250和50/500μg）相当。茚达特罗在健康状况方面也有望与FOR / BUD（9/320和9/160μg）和SAL / FP 50/500μg相媲美，在SAL / FP（50/250和50/500μg）中相媲美。呼吸困难

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号